Sona Nanotech Inc (TSE:SONA) has released an update.
Sona Nanotech Inc. has announced the appointment of Dr. Carman Giacomantonio as Chief Medical Officer, bringing his expertise in cancer immunotherapy to lead the company’s Targeted Hyperthermia Therapy clinical trials. Additionally, Sona has filed a U.S. provisional patent for a gold nanorod conjugation technique aimed at targeted drug delivery, with plans to expand it to international patents. Dr. Giacomantonio has been granted 750,000 stock options as part of the company’s incentive plan, enhancing his involvement in their innovative medical technologies.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.
